The HBM4EU Scoping document on cadmium and chromium VI Scoping document on cadmium and chromium VI  (December 2020) provides background information on these substances, identifies relevant policy questions on the group of substances and outlines research activities under HBM4EU.

The lead authors of the scoping document were Milena Horvat of the Jožef Stefan Institute and Alessandro Alimonti of the Italian National Institute of Health. The document was produced in December 2020.

Click here to read a report on HBM4EU activities on cadmium from 2020.

A mapping of the legislative status of cadmium in the European Union is available here.

A number of communication products have been developed for Cadmium, such as the policy briefinfographicsubstance report and video.

Uses of Cadmium

Cadmium levels in the environment vary widely and are a consequence of both natural (erosion of parent rocks, volcanic eruptions, forest fires; 10-50 %) and anthropogenic sources (used in : plastics as colour pigment and stabilizer, automobile radiators, alkaline batteries, mining activities, fertilizers, sewage sludge, inappropriate waste disposal; 50-90%). During the twentieth century the world consumption of Cd has increased continuously to a global supply of 22,000 metric tons (International Cadmium Association, 2002) and it has remained at this level since 2000. Cadmium is normally transported between the three main environmental compartments: air, water and soil. For more information on cadmium levels in these compartments please see the scoping document here.

Hazardous properties of Cadmium

Cadmium is a potentially toxic metal that ranks 7th on the priority list of hazardous substances of US Agency for Toxic Substances and Disease Registry’s (ATSDR). International Agency for Research on Cancer (IARC) has classified cadmium and cadmium compounds as human carcinogens (Group 1). Chronic occupational exposures (~45 years) to Cd in the air at concentrations of 5-10 µgCd/m3 could lead to renal tubular damage in some of exposed workers and exposure to higher levels of 100 µgCd/m3 may result in obstructive lung disease (Nordberg et al., 2015). Experimental studies showed that Cd can induce lung and prostate cancer in laboratory animals and some epidemiological studies have also found increased rates of cancer in the same and some other organs (Nordberg et al., 2015).

Kidneys, as a major location of Cd accumulation, are primary organ of adverse metal effects that occur at general population after lifelong exposure resulting in urine concentrations of 4 µg Cd/g creatinine. The same level of exposure in more sensitive groups (pregnant and postmenopausal women, elderly) can also lead to bone effects such as osteoporosis and increased risk of fractures. The existence of Cd adverse effects at lower environmental exposures (<1 µg Cd/g creatinine) – related to bone diseases, effects on kidney functions, effects on endocrine system, reproduction and development ect. – has been recently seriously questioned (Åkesson et al., 2014; Nordberg et al., 2015; Apostoli and Catalani 2015; Bernard, 2016).

However, Cd co-exposure and effects in mixtures of chemicals has not been addressed sufficiently. Most experimental and human studies are dealing with exposure to a single element while real environmental exposure is generally characterised by many substances in unpredictive combinations or exposure conditions and by essential metal status (Apostoli and Catalani 2015, Nordberg 2015).

Hexavalent Chromium

Chromium can exist in oxidation states ranging from -2 to +6, but is most frequently found in the environment in the trivalent (+3) and hexavalent (+6) oxidation states. The +3 and +6 forms are the most important as the +2, +4, and +5 forms are unstable and are rapidly converted to +3, which in turn is oxidised to +6 (Towill et al. 1978). Hexavalent form – Cr(VI) – is more toxic than trivalent form.

  • Cr(III) for its high oxidising potential – and easily penetrates biological membranes.

Hexavalent chromium was classified by IARC as a human carcinogen (Group 1) associated with increased lung cancer risk among workers in certain industries and also cancer of the nose and nasal sinuses.

In EU the estimated number of Cr(VI)-exposed workers in 2012 was ~786,000, with the largest numbers exposed to welding (IARC, 2012). In the EU CLP Regulation (EC) No 1272/2008 they are classified as genotoxic (Muta. 1B) and as carcinogen (Carc. 1B or 1A).

Also the dermal exposure to Cr(VI) compounds can cause skin irritation, ulceration, sensitization, and allergic contact dermatitis (NIOSH, 2002). The toxicity of Cr(VI) in humans has been reviewed extensively (ATSDR, 2012; Costa and Klein, 2006; U.S. EPA 1998). After absorption, mainly via inahalation for workers and/or via ingestion for the general population, Cr(VI) readily penetrates cell membranes. The details of Cr(VI) toxic activity assumed that genotoxicity, including a wide variety of effects such as DNA damage, gene mutation, sister chromatid exchange, chromosomal aberrations, cell transformation, and dominant lethal mutations, may be due to the reduced forms of intracellular origin, formed by the reduction of Cr(VI) to Cr(III) (Stearns et al., 1995). The main protection mechanism against Cr(VI) activity in the lungs and the stomach is the extracellular reduction of Cr(VI) to Cr(III) by a NADPH-dependent mechanism involving ascorbate (De Flora et al., 2000). Animal trials show that glutathion plays an important role in Cr(VI) reduction in erythrocytes, also showing certain reduction activity in the lungs (Suzuki and Fukuda, 1990).

Human exposure to Cadmium (Cd) and Cr(VI)

General population is exposed to Cd primarily through diet and drinking water (5-10 % of ingested Cd is absorbed), and tobacco smoke (10-50 % of inhaled Cd is absorbed). The mean exposure of adults in Europe and North America through food is 10-20 µg Cd/day, which results in average urinary excretion of 0.5-1.0 µg Cd/day and blood concentrations of 0.5-1.0 µgCd/L for non-smokers (twice as high in smokers) (Nordberg et al., 2015).

At the European level the biomarkers are collected in national HBM programs (German Environmental Survey, GerES; The Flemish Environment and Health Study, FLEHS; French Nutrition and Health Survey, ENNS; Czech Republic HBM, CZ-HBM; Slovenian National HBM; etc.) and international projects (Public health impact of long-term, low-level mixed element exposure in susceptible population strata, PHIME and DEMOnstration of a study to COordinate and Perform Human Biomonitoring on a European Scale, COPHES/DEMOCOPHES).

Health-based reference values for cadmium in urine are 1 µg/L (µg/g creatinine; HBM I) and 4 µg/L (µg/g creatinine; HBM II) for adults, and 0.5 µg/L (µg/g creatinine; HBM I) and 2 µg/L (µg/g creatinine; HBM II) for children, as set by the German Human Biomonitoring Commission (Schulz et al., 2011). In blood, reference value is below 1 μg/L for adults (Wilhelm et al., 2004).


Breathing contaminated workplace air is the main source in occupational setting. For the general population exposure to Cr occurs primarily by ingestion of Cr-contaminated soil, food, and water, but also through inhalation of ambient air. Cigarette smoking is another important source of Cr exposure, including the hexavalent state. When talking about total Cr, it is accepted that the contribution of drinking water to the total exposure is substantial only when levels are above 25 μg/L (WHO, 2003). However, the EFSA Panel on Contaminants in the Food Chain noted that the contribution of drinking water to total Cr refers to Cr(VI), whereas in food the trivalent form Cr(III) is the major form. Mean chronic exposure assessment for Cr(VI) across European dietary surveys through the consumption of drinking water ranged from 0.7 ng/kg b.w. per day to 159.1 ng/kg b.w. per day (EFSA, 2014).

Biological monitoring of exposure to Cr(VI) compounds is a practice in occupational settings. In workers, the distribution of inhaled Cr(VI) permits the biological monitoring of Cr in urine, whole blood, plasma, and blood cells. Relevant biological monitoring guidance values for occupational exposure to Cr have been reported on a national basis, but not at EU level. The Spanish authorities set a biological limit value (BLV) for total Cr concentration of10 μg/L in urine measured during a shift and 25 μg/L at the end of the workweek (INSHT, 2016). In the UK, a biological monitoring guidance value (BMGV) of 10 μmol/mol creatinine in post shift urine was established (HSE, 2011).

In Germany, in order to help interpretation of occupational biomonitoring results, DFG did set a BAR (Biologischer Arbeitsstoff-Referenzwert) for the general not occupationally exposed population of working age of 0.6 μg/L urine for Cr(VI) compounds (inhalable fraction) (DFG, 2012). DFG further established the DFG-EKA values (biological exposure equivalents for carcinogenic substances) for Cr(VI) that set the range of total Cr in urine (form 10 µg/L to 40 µg/L) and in erythrocyte fraction of whole-blood (form 9 µg/L to 35 µg/L) if soluble alkaline chromate of a certain concentration and/or hexavalent welding fumes (only for urine) were inhaled over a work shift (DFG, 2015).

No HBM survey have been performed at EU level on Cr(VI) exposure of the general population. Few Human Biomonitoring data come from individuals accidentally or intentionally ingesting Cr(VI)

Technical challenges in biomonitoring Cadmium in humans

Biomarkers related to low environmental cadmium exposure currently commonly used are (Nordberg et al., 2015, Bernard et al 2016) are levels of:

  • Cd in urine is usually accepted as biomarker of body burden reflecting long term accumulation, but such definition is limited to occupational or really excessive exposures. At low environmental situations urine Cd levels are influenced by several factors including physiological variations related to normal (age, circadian rhythm) and stress conditions (physical stress, smoking) or silent (undercurrent) pathophysiological conditions. All these factors are affecting kidney pathways and co-excretion patterns of renal functional biomarkers and Cd itself. Co-excretion of Cd and proteins adds uncertainty to the relationship between UCd and the body burden of Cd.
  • Cd in blood /plasma (in most laboratories chemical analyses are not sensitive enough to permit the accurate measurement of plasma or serum). At low Cd levels blood represents recent and past exposure; they cannot be properly distinguished.
  • Cd in placenta is used as indicator of Cd exposure during pregnancy
  • Cd in cord blood is indicating Cd transfer from maternal blood to cord blood
  • Cd in feces – at low doses comparable with urine excretion)
  • Cd in kidney, liver or bone tissues is reflecting Cd accumulation.
  • Renal function biomarkers in urine such as: albumin (Alb) and Imunoglobulin G (IgG) indicating glomerular kidney damage, and N-acetyl-beta-D-glucosaminidase (NAG), α1- microglobulin (A1M), β2 microglobulin (B2M), retinol-binding protein (RBP), Kidney Injury Molecule-1 (KIM-1), metallothioneins (MTs) indicating tubular kidney damage (Nordberg et al., 2015) – at low levels they rather function as indicators of normal physiological processes, so they are unrepresentative for Cd risk assessment at low levels.

The most common methods for Cd determination in human matrices are inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption spectrophotometry (AAS) and atomic fluorescence spectrophotometry (AFS). For the in vivo determination of Cd in tissues, X-ray fluorescence is used. For the determination of renal function biomarkers in urine the standard nephelometric immunochemical method is used, which is less accurate than the measurement of Cd levels in urine or blood. Therefore, determination of renal function biomarkers in relation to Cd exposure and health risk assessment is more reliable at high Cd exposures (> 4 µgCd/ml).

Biomarkers related to Cr(VI) exposure are, currently, the followings:

An important consideration in biological testing for Cr(VI) is the reduction of Cr(VI) to Cr(III) throughout the body. Basically, inhalation is the primary route of concern for occupational Cr(VI) exposure. Inhaled Cr(VI) enters the respiratory system, where it may remain, be reduced, or enter the bloodstream. Cr(VI) may be reduced to Cr(III) in the lungs or plasma and excreted as Cr(III) in the urine. Cr(VI) that is not reduced in the plasma may enter erythrocytes and lymphocytes. This distribution of absorbed Cr(VI) permits the biological monitoring of Cr in urine, whole blood, plasma, and red blood cells (RBCs) in occupational settings.

  • Cr in urine

Urinary Cr levels are a measure of total Cr exposure as Cr(VI) is reduced within the body to Cr(III). The average urinary excretion half-life of Cr(VI) is about 39 h.

  • Cr measurements in blood and plasma

Plasma or whole blood Cr levels are indicative of total Cr exposure because Cr(VI) may be reduced to Cr(III) in the plasma. Moreover many variables can affect Cr levels in the blood, including diet, varying rates in gastrointestinal absorption, and individual capacity to reduce Cr(VI).

  • Cr measurements in red blood cells (RBCs)

Intracellular Cr levels are indicative of Cr(VI) exposure because Cr(VI) passes through cell membranes, while Cr(III) does not. The Cr concentration inside erythrocytes indicates exposure to Cr(VI) sometime during the approximate 120-day lifespan of the cells. There are two advantages to the monitoring of Cr levels in RBCs versus urine: i), the sampling time may be relatively independent of the time of exposure, and, ii), it permits the determination of Cr(VI), rather than only total chromium, absorption.

Thus, in principle, erythrocyte Cr concentration was recommended for its specificity but limited by its low sensitivity. Plasma Cr concentration was recommended as a sensitive parameter, limited by its lack of specificity.

  • Cr measurements in exhaled breath condensate (EBC)

In the last years also the exhaled breath condensate (EBC) is depicted as a very good biomarker of occupational exposure. This could potential be a non-invasive alternative to measure exposure to Cr(VI) compounds long after exposure.

In any case, the above biomarkers of exposure are not sufficiently validated and great efforts could be made in this sense. In addition, while biomonitoring of occupationally exposed workers has been used to assess high-level inhalation exposures in the workplace, evaluating low-level environmental exposure to Cr(VI) has to be still addressed.

Moreover, the inter- and intrapersonal variability in background levels of Cr is known to be significant and influenced by food and beverage intake, smoking, exercise, habits. Thus, the role of each factor must be carefully understood.

Overview of the biomoritoring methods is available for total Cr in occupational setting. The DFG proposed two regulatory methods: the first for total Cr in urine, the second for total Cr in whole blood as well as in plasma and in erythrocytes. The analytical determination is done using a standard graphite or a pyrolytically coated graphite tube in combination with electrothermal atomic absorption spectroscopy (EAAS) (detection limit were 0.1 μg /L and 0.5 μg /L) (DFG, 1990). Other analytical techniques for total Cr determination in human matrices is inductively coupled plasma mass spectrometry (ICP-MS).

Because Cr(VI) is largely reduced to Cr(III) in the body, speciation of Cr could not be useful in HBM programmes. However, several methods aiming at direct or indirect measurement of Cr(VI) have been published in literature. They are usually based on some kind of separation of Cr(III) and Cr(VI) (i.e., micro liquid chromatography (µLC) system or ion chromatography), followed by ICP-MS quantification (detection limits ranging from 0.1 to 1.0 μg/L).

However, as far as know, none of these methods have obtained the status of regulatory method yet nor have they undergone a validation.

Legislative status in the European Union


Following on the Advisory Board’s advice to strengthen the science-policy interface, HBM4EU developed a strategic and systematic approach to outreach and align science and policy. A legislative mapping exercise was done by RPA Consultants, providing relevant public policy processes that may benefit from the knowledge generated under HBM4EU. The documents are available for consultation here, with the tables presented here.

Since cadmium is listed in Regulation (EC) No 1272/2008 as human carcinogen, (Carc. 1B) and due to its increasing evidence of toxicity, both national and international agencies have sought to regulate its exposure. The WHO (2004) guidelines for drinking water quality has been revised from 5 to 3 μgCd/L and WHO (2000) guidelines for ambient air 5 ngCd/L. The Joint FAO/WHO Expert Committee on Food Additives (JECFA, 2012) has recommended a maximum intake from food of 25 μg/kg bw/month (Nordberg et al., 2015). The main rational for action/inaction lies in Regulation (EC) No. 1881/2006 of 19 December 2006 that sets maximum levels for certain contaminants in foodstuffs and contains the most recent maximum levels for Cd in foodstuffs. Furthermore, use of Cd is restricted in certain products (Annex XVII of REACH), among them recycled PVC, the existing allowed limit of which is currently in review. There is also ongoing discussion as regards allowable maximum levels in phosphate fertilizers with a link to acceptable maximum levels in food. Overall, the levels in food, recycled PVC and fertilizers continue to be reviewed by the Commission. An updated scientific basis is therefore of great importance.          

Hexavalent Chromium

In the case of Cr(VI) compounds an oral minimal risk level (MRL) of 0.005 mg/kg b.w. per day was derived for intermediate (15-364 days) exposure based on haematological effects in rats, while reported in a chronic drinking water study (> 1 year) an oral MRL of 0.001 mg/kg b.w. per day was derived selecting as critical effect non-neoplastic lesions of the duodenum (ATSDR, 2012). The WHO derived an oral tolerable daily intake (TDI) for non-cancer effects of 0.9 μg CrVI/kg b.w. per day taking into account the data relative to outcome observed in female mice after exposure to sodium dichromate dehydrate in drinking-water (WHO/IPCS, 2013). In a recent document, EFSA provided information on benchmark doses, margin of exposure (MOE) and TDI for the European population (EFSA, 2014).

To date no EU regulation regarding maximum levels of total Cr in food has been established.

A maximum value of 50 μg Cr/L for total Cr both in water intended for human consumption and in natural mineral waters are reported by the Council Directive 98/83/EC and the Commission Directive 2003/40/EC, but no level is available specifically for Cr(VI).

In air, the EU proposed an OEL (occupational Exposure Limit) for the hazardous Cr(VI) of 25 μg/m3; the number of future cancer cases can be most substantially decreased through full compliance with the OEL( In addition, the Occupational Safety and Health Administration (OSHA) has established a permissible exposure limit (PEL) of 5 μg/m3 and an action level (AL) of 2.5 μg/m3; both for a 8-hour time-weighted average (TWA) exposure to Cr(VI) (OSHA, 2006). The National Institute for Occupational Safety and Health (NIOSH) has recommended a 10-hour TWA exposure limit for all Cr(VI) compounds of 1 µg Cr(VI)/m³ (NIOSH, 2013).

Hexavalent Cr is included in the revised Annex XIV to the EU REACH Regulation; inclusion in this Annex means that in order to continue to use chromium trioxide and other hexavalent chromium compounds after 21 September 2017, an authorisation will be required.

In addition, since 1 May 2015 a restriction on Cr(VI) in leather is in place (EU Regulation 301/2014) and applicable at EU level (limit of 3 ppm). That threshold is expected to be 80 % effective in reducing the occurrence of new Cr(VI)-related allergic dermatitis cases due to Cr(VI) in leather articles.

Moreover, current migration limits for Cr(VI) are laid down in the Toy Safety Directive 2009/48/EC for ensuring the safety of toys. The current migration limits for Cr(VI) from toys are: 0.2 mg/kg toy for scraped-off toy materials, 0.02 mg/kg toy material for dry (powder-like or pliable) toy materials and 0.005 mg/kg toy material for liquid or sticky toy materials, respectively.

Regarding cosmetics, because of its allergenic character, the presence of Cr(VI) is prohibited in cosmetics by a German cosmetics regulation and also by the corresponding new EU Cosmetics Directive (EU) No 1223/2009; the only allowable green colorants are those based on the trivalent form of Cr (chromium hydroxide green (Cr2O(OH)4) and chromium oxide green (Cr2O3)).

Policy questions on Cadmium

Throughout the duration of this project, the following policy questions will be addressed:

  1. Policy questions related to Cd:
    1. What is the current (last 10 years) exposure of the European population to Cd?
    2. Does the exposure to Cd differ significantly between countries and population groups? What are the main reasons for differences in exposure?
    3. Is there a significant time trend of Cd levels in existing population studies?
    4. Is there a link between high soil contamination with Cd and human exposure via dietary sources?
    5. Which populations are most at risk?
    6. Are the overall exposure levels (in different population groups) above any health-relevant assessment levels (HBM guidance values, TDI)?
    7. Has the regulation under REACH had the favourable impact like a reduction of GM/median concentrations?
    8. Are environmental quality standards for Cd in water sufficiently restrictive to protect human health from exposure to Cd via the environment and via dietary sources?
    9. Using EU food consumption data, are current Cd food maximum levels sufficiently health protective?
    10. Can input be given to the decision as to whether the exemption for Cd in quantum dots under the RoHS Directive can be scrapped?


Policy questions related to Cr(VI):

  1. What is the level of exposure to Cr(VI) occupationally relevant in the EU population?
  2. Does the exposure to Cr(VI) differ significantly between countries and population groups?
  3. What are the groups at risk (e.g. by industrial sector)?
  4. Are the exposure levels (in different population groups) above any health-relevant assessment levels (HBM guidance values, BLV, OEL)?
  5. Have the newly collected HBM data on Cr(VI) an impact in risk assessment procedures (e.g. REACH)?
  6. Which are the appropriate HBM matrices, methods and biomarkers for Cr(VI)?
  7. Which are possible health effects resulting from exposure to Cr(VI)?
  8. Which are possible mechanistic explanation and AOPs for Cr(VI)?
  9. Which are the effects of metals mixtures?

Stakeholder comments on the scoping document

In the interest of transparency and accountability, HBM4EU invites interested stakeholders to submit comments on the scoping document.

All submitted comments will be made available for download on this webpage and will be taken into consideration by the HBM4EU consortium, where possible.

Please click here to submit your comments.

Substance Report

Please click here to access the Substance Report.


  1. Åkesson, A., Barregard, L., Bergdahl, I. a, Nordberg, G.F., Nordberg, M., Skerfving, S., 2014. Non- renal effects and the risk assessment of environmental cadmium exposure. Environ. Health doi:10.1289/ehp.1307110
  2. Apostoli, P., Catalani, S., 2015. Effects of Metallic Elements on Reproduction and Development, in: Nordberg, G.F., Fowler, B.A., Nordberg, M. (Eds.), Handbook on the Toxicology of Metals. Elsevier, Academic Press, USA, pp. 399 –
  3. 2012. Toxicological Profile for Chromium. Available at:
  4. Bernard, A., 2016. Confusion about cadmium risks: The unrecognized limitations of an extrapolated paradigm. Environ. Health Perspect. 124, 1–5. doi:10.1289/ehp.1509691
  5. Blade, L.M., Yencken, M.S., Wallace, M.E. et al. 2007. Hexavalent chromium exposures and exposure-control technologies in American enterprise: results of a NIOSH field research study. Occup. Environ. Hyg. 4, 595–618
  6. Costa, M., Klein, C.B. 2006. Toxicity and carcinogenicity of chromium compounds in humans.Crit Rev Toxicol. 36(2), 155-63.
  7. De Flora, S. 2000. Threshold mechanisms and site specificity in chromium(VI). Carcinogenesis. 21(4):533-41.
  8. DFG 2012. DFG [Deutsche Forschungsgemeinschaft] (2012a) Alkali chromates (Cr(VI)) [BAT Value Documentation, 1994]. M. Bolt, J. Lewalter. DOI: 0.1002/3527600418.bb0ek1e0001. The MAK Collection for Occupational Safety and Health. Published online 31 Jan 2012. Retrieved 27 September, 2016. Available at:
  9. 2015. [Deutsche Forschungsgemeinschaft] (2015) List of MAK and BAT Values 2015. Page 243. Retrieved 27 September, 2016. Available at:
  10. 2011. [Health and Safety Executive] (2011) EH40/2005 Workplace Exposure Limits. EH40 (Second edition. published 2011). Health and Safety Executive (HSE). UK. Retrieved 27 September, 2016, from
  11. 2012. Monographs on the Evaluation of Carcinogenic Risks to Humans. Chromium (VI) Compounds. Volume 100C Lyon, France: International Agency for Research on Cancer, Available at:
  12. INSHT 2016. [Instituto Nacional de Seguridad e Higiene en el Trabajo] (2016). Límites de Exposición

Profesional para Agentes Químicos en Espana. Spain. Retrieved 27 September, 2016. Available at: 0limite/Limites2016/LEP%202016.pdf

  1. European Chemical Agency, 2013. Support document for identification of
  2. National Institute for Occupational Safety and Health, 2002. NIOSH comments on the Occupational Safety and Health Administration request for information on occupational exposure to hexavalent chromium (CrVI): OSHA Docket No. H-0054a. NIOSH policy statements. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. Available online: )
  3. National Institute for Occupational Safety and Health, 2013. Occupational Exposure to Hexavalent Chromium.National Institute for Occupational Safety and Health Occupational Exposure (NIOSH). Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. Available online: 128/pdfs/2013_128.pdf
  4. Nordberg, G.F., Nogawa, K., Nordberg, M., 2015. Cadmium, in: Nordberg, G.F., Fowler, A., Nordberg, M. (Eds.), Handbook on the Toxicology of Metals. Elsevier, Academic Press, USA, pp. 667– 716.
  5. Office of Environmental Health Hazard Assessment (OEHHA, 2011). Public Health Goals for Chemicals in Drinking Water. Hexavalent Chromium (Cr VI). Available online:
  6. Occupational Safety and Health Administration, 2006. Occupational Exposure to Hexavalent Chromium. Washington, DC: Department of Labor, Occupational Safety and Health Administration (OSHA). Available online:
  7. Schulz, C., Wilhelm, M., Heudorf, U., Kolossa-Gehring, M., 2011. Update of the reference and HBM values derived by the German Human Biomonitoring Commission. Int. J. Hyg. Environ. Health 215, 26–35. doi:10.1016/j.ijheh.2011.06.007
  8. Scientific Opinion of the Panel on Contaminants in the Food Chain on on the risks to public health related to the presence of chromium in food and drinking water. The EFSA Journal 2014, 12(3), 3595.
  9. Stearns, D.M., Kennedy, L.J., Courtney, K.D., Giangrande, P.H., Phieffer, L.S., Wetterhahn, K.E. 1995. Reduction of chromium (VI) by ascorbate leads to chromium DNA-binding and DNA strand breaks in vitro. Biochemistry 34, 910–919.
  10. Suzuki, Y., Fukuda, K. 1990. Reduction of hexavalent chromium by ascorbic acid and glutathione with special reference to the rat lung. Arch Toxicol. 64, 169–176.
  11. Tóth, G., Hermann, T., Da Silva M.R., Montanarella L. 2016 Heavy metals in agricultural soils of the European Union with implications for food safety. Env. Int. 88, 299–309.
  12. Towill, L.E., Shriner, C.R., Drury, J.S., Hammons, A.S., Hollema,n J.W. 1978. Reviews of the environmental effects of pollutants: III chromium. U.S. Environ. Protection Agency Rep. 600/1-78-023. 287
  13. S. EPA. Support of Summary Information on the Integrated Risk Information System (IRIS) Washington DC: U.S. Environmental Protection Agency; 1998. Toxicological Review of Hexavalent Chromium (CAS No 18540-29-9).
  14. WHO (World Health Organisation). 2000. Air Quality Guidelines, second edition. Chapter 4 – Chromium‖. Regional Office for Europe, World Health Organization (Copenhagen). Available at: data/assets/pdf_file/0017/123074/AQG2ndEd_6_4Chromium  .
  15. WHO (World Health Organization). 2003. Chromium in drinking water — Background document for development of WHO ―Guidelines for drinking-water quality‖. WHO/SDE/WSH/03.04/04, World Health Organization (Geneva). Available at:
  16. WHO/IPCS (World Health Organization/International Programme on Chemical Safety). Inorganic chromium (VI) compounds. Concise International Chemical Assessment Document 78. Available at:
  17. Wilhelm, M., Ewers, U., Schulz, C., 2004. Revised and new reference values for some trace elements in blood and urine for human biomonitoring in environmental medicine. Int. J. Hyg. Environ. Health 207, 69–73. doi:10.1078/1438-4639-0026.


The HBM4EU project was launched in 2016 with the aim of improving the collective understanding of human exposure to hazardous chemicals and developing HBM as an exposure assessment method. The project had €74m in funding and jointly implemented by 120 partners from 28 participating countries – 24 EU member states plus Norway, Switzerland, Iceland and Israel and the European Environment Agency. One of its aims was to ensure the sustainability of HBM in the EU beyond 2021. The project ended in June 2022. The website will not be updated any longer, except the page on peer reviewed publications, but will be online until 2032.